Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Lung Cancer

    Glendale, AZ

    Search
    Lung Cancer
    Glendale, AZ
    Show Map
    Map View
    Glendale, AZ
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      168 Lung Cancer Trials near Glendale, AZ

      Power is an online platform that helps thousands of Lung Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      GD2-SADA:177Lu-DOTA Complex for Small Cell Lung Cancer

      Scottsdale, Arizona
      This trial tests a new treatment for certain cancers using a two-part method. The first part finds and attaches to cancer cells, and the second part delivers radiation to kill them. It aims to see if this treatment is safe and can be tolerated by patients with Small Cell Lung Cancer, Sarcoma, and Malignant Melanoma.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:16+

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Diseases, HIV, Hepatitis, Others
      Must Not Be Taking:Investigational Therapies

      60 Participants Needed

      Dabrafenib + Trametinib Access for Cancer

      Scottsdale, Arizona
      This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Unresolved Toxicities, Commercial Availability, Others
      Must Be Taking:Dabrafenib, Trametinib

      100 Participants Needed

      RP1 + Nivolumab for Cancer

      Phoenix, Arizona
      This trial tests a modified virus (RP1) and an immune-boosting drug (nivolumab) in adults with advanced or treatment-resistant solid tumors. RP1 kills cancer cells and helps the immune system recognize them, while nivolumab enhances the immune response. Nivolumab has been approved for treating advanced melanoma, renal cell carcinoma, non-small cell lung cancer, and other malignancies.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastasis, Lung Disease, Cardiovascular, Others
      Must Not Be Taking:Antivirals

      340 Participants Needed

      ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer

      Scottsdale, Arizona
      This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active Brain Metastasis, Active Infection, Others
      Must Not Be Taking:Chronic Steroids

      733 Participants Needed

      CM24 + Nivolumab for Solid Tumors

      Scottsdale, Arizona
      This trial tests a combination of new and existing drugs to treat patients with severe forms of cancer. The treatment aims to boost the immune system's ability to fight cancer and directly kill cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      79 Participants Needed

      ST-067-001 for Solid Tumors

      Scottsdale, Arizona
      This trial is testing a new drug called ST-067 on patients with certain types of cancer that have not responded to previous treatments. The goal is to find the safest and most effective dose and to see how well it works against these cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disorders, Brain Metastases, Cardiovascular Disease, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      316 Participants Needed

      CLSP-1025 for Cancer

      Scottsdale, Arizona
      Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Li-Fraumeni Syndrome, Active Infection, Others

      90 Participants Needed

      MRTX1719 for Solid Tumors

      Phoenix, Arizona
      This trial is testing a new drug, MRTX1719, for patients with advanced cancers that have a specific genetic deletion. The drug aims to kill cancer cells by exploiting a weakness caused by this genetic change.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Hemorrhage, Cardiac Abnormalities, Others
      Must Not Be Taking:PRMT5, MAT2A Inhibitors

      336 Participants Needed

      Sonidegib + Pembrolizumab for Advanced Cancers

      Scottsdale, Arizona
      This trial tests the best dose of sonidegib combined with pembrolizumab for treating advanced solid tumors. Sonidegib blocks enzymes needed for tumor growth, while pembrolizumab helps the immune system attack cancer. The study focuses on patients with advanced cancers that have spread, aiming to find a more effective treatment than standard options.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Neuromuscular Disorders, Autoimmune Diseases, Others
      Must Not Be Taking:Statins, CYP3A4 Inhibitors

      36 Participants Needed

      LY4170156 for Breast Cancer

      Scottsdale, Arizona
      The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Carcinomatous Meningitis, Infections, Others

      495 Participants Needed

      AB308 + Zimberelimab for Advanced Cancers

      Phoenix, Arizona
      This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Recent Surgery, Others
      Must Not Be Taking:Anti-TIGIT, Immunotherapy

      94 Participants Needed

      XL092 + Immuno-Oncology Agents for Solid Tumors

      Phoenix, Arizona
      This trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Uncontrolled Illness, Pregnancy, Others
      Must Not Be Taking:Anticoagulants, Complementary Medicines

      1274 Participants Needed

      Cabozantinib for Pancreatic Neuroendocrine Tumors

      Phoenix, Arizona
      This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Congestive Heart Failure, Cardiac Arrhythmia, Hypertension, Others
      Must Not Be Taking:Warfarin, Strong CYP3A4 Inhibitors

      298 Participants Needed

      CRX100 for Solid Cancers

      Scottsdale, Arizona
      This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, hepatocellular carcinoma (HCC), malignant melanoma (excluding uveal melanoma), gastric cancer, triple negative breast cancer, and osteosarcoma. The study will start with monotherapy dose escalation followed by combination cohorts.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastasis, Active Infections, Autoimmune Disease, HIV, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      60 Participants Needed

      Cabozantinib + Atezolizumab for Advanced Cancers

      Phoenix, Arizona
      This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      914 Participants Needed

      HFB200301 + Tislelizumab for Advanced Cancers

      Scottsdale, Arizona
      This trial tests a new drug, HFB200301, alone and with another drug, tislelizumab, in adults with advanced cancers. Researchers will start with a low dose and gradually increase it to find the most suitable amount. They will then test this amount in more patients to see how well it works against different cancers.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Uncontrolled Diabetes, Others
      Must Not Be Taking:Steroids, Immunosuppressants, CYP450 Substrates

      72 Participants Needed

      9-ING-41 for Advanced Cancers

      Phoenix, Arizona
      GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Cardiovascular Impairment, Brain Metastases, Others

      350 Participants Needed

      DF9001 + Nivolumab for Solid Tumors

      Phoenix, Arizona
      This trial is testing a new molecule that helps the immune system attack cancer cells. It focuses on patients with solid tumors that have a protein called EGFR. The study will determine the best dose and test its effectiveness alone and with another drug called pembrolizumab. AM0010 has been previously tested in combination with pembrolizumab for advanced cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Autoimmune Disease, Infections, Others
      Must Not Be Taking:Immunosuppressants, Steroids

      242 Participants Needed

      Avelumab for Cancer

      Scottsdale, Arizona
      The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Hypersensitivity, Others
      Must Be Taking:Avelumab

      205 Participants Needed

      WTX-124 + Pembrolizumab for Solid Tumors

      Scottsdale, Arizona
      This trial tests a new medicine called WTX-124, alone and with pembrolizumab, in patients with severe forms of skin and kidney cancer. WTX-124 helps the immune system attack cancer cells, and pembrolizumab makes it easier for the immune system to see these cells.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Pneumonitis, Autoimmune, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      150 Participants Needed

      Why Other Patients Applied

      "I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

      EQ
      Lung Cancer PatientAge: 70

      "My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

      OF
      Cholangiocarcinoma PatientAge: 54

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

      FR
      Lung Cancer PatientAge: 71

      "I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

      UM
      Pancreatic Cancer PatientAge: 48
      Match to a Lung Cancer Trial

      IMC-F106C Combinations for Solid Cancers

      Scottsdale, Arizona
      This trial tests IMC-F106C, a treatment that helps the immune system target and kill cancer cells in adults with advanced cancers. It guides immune cells to attack cancer cells more effectively.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastasis, Lung Disease, Others
      Must Not Be Taking:Antibiotics, Vaccines

      727 Participants Needed

      NDI-101150 + Pembrolizumab for Cancer

      Scottsdale, Arizona
      This trial is testing a new drug called NDI-101150, alone or with pembrolizumab, in adults with advanced cancers. It aims to find the safest dose and see how well it works. Pembrolizumab helps the immune system attack cancer cells and is used to treat various cancers.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      106 Participants Needed

      FOG-001 for Cancer

      Scottsdale, Arizona
      This trial is testing FOG-001, a new medicine, to see if it is safe and effective for patients with advanced or spreading solid tumors. FOG-001 works by blocking certain proteins to stop cancer cells from growing.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Bone Metastasis, Osteoporosis, Inflammatory Bowel Disease, Others

      575 Participants Needed

      Dato-DXd + Pembrolizumab for Non-Small Cell Lung Cancer

      Chandler, Arizona
      This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Prior NSCLC Treatment, CNS Metastases, Others
      Must Not Be Taking:Topoisomerase Inhibitors, TROP2 Therapies

      1170 Participants Needed

      Dato-DXd + Pembrolizumab for Advanced Lung Cancer

      Chandler, Arizona
      This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Prior NSCLC Treatment, CNS Metastases, Others
      Must Not Be Taking:Topoisomerase Inhibitors, TROP2 Therapies

      740 Participants Needed

      Lurbinectedin +/- Irinotecan for Small Cell Lung Cancer

      Chandler, Arizona
      Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Heart Disease, Liver Disease, HIV, Others
      Must Not Be Taking:Topoisomerase Inhibitors

      705 Participants Needed

      DS-1062a for Lung Cancer

      Phoenix, Arizona
      This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiovascular Disease, ILD, Others
      Must Be Taking:Targeted Therapy

      137 Participants Needed

      Dato-DXd + Pembrolizumab for Lung Cancer

      Scottsdale, Arizona
      This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Organ Transplant, CNS Metastases, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressants

      145 Participants Needed

      Chemoradiation + Pembrolizumab/Olaparib for Small Cell Lung Cancer

      Chandler, Arizona
      Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:MDS/AML, Immunodeficiency, Autoimmune, Others
      Must Not Be Taking:Anti-PD-1, PARP Inhibitors

      672 Participants Needed

      EGFR Inhibitor for Brain Cancer

      Scottsdale, Arizona
      This trial is testing a new drug called WSD0922-FU for patients with aggressive brain and spinal cord cancers. The drug works by blocking a protein that helps cancer cells grow. The goal is to find the best dose and see if it can effectively treat these hard-to-treat cancers.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, Hepatitis, Others
      Must Be Taking:EGFR TKIs

      55 Participants Needed

      123456

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Lung Cancer clinical trials in Glendale, AZ pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Lung Cancer clinical trials in Glendale, AZ work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Lung Cancer trials in Glendale, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Glendale, AZ for Lung Cancer is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Glendale, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Lung Cancer medical study in Glendale, AZ?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Lung Cancer clinical trials in Glendale, AZ?

      Most recently, we added BMS-986504 + Pembrolizumab + Chemotherapy for Lung Cancer, Multiple Treatments for Non-Small Cell Lung Cancer and Neladalkib for Non-Small Cell Lung Cancer to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Arizona

      Anxiety Clinical Trials in Arizona

      Schizophrenia Clinical Trials in Arizona

      ADHD Clinical Trials in Arizona

      Bipolar Disorder Clinical Trials in Arizona

      Multiple Sclerosis Clinical Trials in Arizona

      Autism Clinical Trials in Arizona

      Treatment Resistant Depression Clinical Trials in Arizona

      Borderline Personality Disorder Clinical Trials in Arizona

      Social Anxiety Disorder Clinical Trials in Arizona

      Parkinson's Disease Clinical Trials in Arizona

      Alzheimer's Disease Clinical Trials in Arizona

      By Location

      Clinical Trials near Phoenix, AZ

      Clinical Trials near Tucson, AZ

      Clinical Trials near Scottsdale, AZ

      Clinical Trials near Mesa, AZ

      Clinical Trials near Chandler, AZ

      Clinical Trials near Tempe, AZ

      Clinical Trials near Gilbert, AZ

      Clinical Trials near Glendale, AZ

      Clinical Trials near Peoria, AZ

      Clinical Trials near Sun City, AZ

      Clinical Trials near Goodyear, AZ

      Clinical Trials near Flagstaff, AZ

      Other People Viewed

      By Subject

      Top Prostate Cancer Clinical Trials near Glendale, AZ

      Top Clinical Trials near Glendale, AZ

      110 Colorectal Cancer Trials near Glendale, AZ

      138 Breast Cancer Trials near Glendale, AZ

      Top Alzheimer's Disease Clinical Trials near Glendale, AZ

      Top Lung Cancer Clinical Trials near Phoenix, AZ

      197 Clinical Paid Trials near Glendale, AZ

      20 Autism Trials near Glendale, AZ

      Top Prostate Cancer Clinical Trials near Phoenix, AZ

      Top Lung Cancer Clinical Trials near Austin, TX

      Top Lung Cancer Clinical Trials near Raleigh, NC

      Top Lung Cancer Clinical Trials near High Point, NC

      By Trial

      Sotorasib for Non-Small Cell Lung Cancer

      GT103 + Pembrolizumab for Non-Small Cell Lung Cancer

      MGY825 for Lung Cancer

      CivaSheet for Lung Cancer

      Pre-Surgical Respiratory Muscle Training for Lung Cancer

      Osimertinib + Necitumumab for Lung Cancer

      NIR Fluorescence-Guided Surgery for Early Stage Lung Cancer

      Immunotherapy + Local Consolidation Therapy for Lung Cancer

      Abemaciclib Combo for Lung Cancer or alternatively, if focusing on breast cancer: Abemaciclib Combo for Breast Cancer

      DS-1062a vs Docetaxel for Lung Cancer

      Radiation Therapy + Durvalumab for Lung Cancer

      Nivolumab + Plinabulin for Lung Cancer

      Related Searches

      Top Lung-cancer Clinical Trials near Los Angeles, CA

      Top Lung-cancer Clinical Trials near Baltimore, MD

      Top Clinical Trials near Ventura, CA

      Top Clinical Trials near Madison, WI

      Top Clinical Trials near Baltimore, MD

      Neuromodulation for Depression

      Omadacycline vs Moxifloxacin for Community-acquired Pneumonia

      Inhaled Treprostinil for Pulmonary Fibrosis

      CAR T-cell Therapy for Pediatric Leukemia & Lymphoma

      CatchU App for Fall Injury Prevention

      PRDR WBRT for Brain Cancer

      BI 1703880 + Ezabenlimab for Advanced Solid Tumors